Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)

Eugènia Negredo, José Moltó, David Burger, Helene Côté, Oscar Miró, Josep Ribalta, Eva Martínez, Jordi Puig, Lidia Ruiz, Juliana Salazar, Sònia López, Julio Montaner, Celestino Rey-Joly, Bonaventura Clotet

Research output: Contribution to journalArticleResearchpeer-review

36 Citations (Scopus)

Abstract

Objectives: To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression. Methods: Pilot study including 31 antiretroviral-experienced patients with HIV RNA <80 copies/mL. Subjects were randomly assigned to lopinavir/ritonavir (LPV/rtv) 400/100 mg BID plus nevirapine (NVP) 200 mg BID (NVP group, n = 16) or LPV/rtv plus the 2 previous NRTIs (NRTI group, n = 15). The primary endpoint was the percentage of subjects who maintained viral suppression at week 48. Changes in lipid metabolism, mitochondrial parameters, and LPV trough levels were also assessed. Results: All patients maintained viral suppression after 48 weeks. No subject discontinued therapy because of adverse events. HDL cholesterol increased by 28% at week 24 (P < 0.0001) and 10% after 48 weeks of follow-up (P = 0.319) in the NVP group. In the NRTI group, LDL cholesterol increased by 14% at week 48 (P = 0.076). Mitochondrial DNA/nuclear DNA ratio and mitochondrial respiratory chain complex IV activity showed a trend toward increasing in the NVP group. Mean (SD) LPV trough levels were 6340 (2129) ng/mL in the NRTI group and 5161 (2703) ng/mL in the NVP group (P = 0.140). Conclusions: In antiretroviral-experienced subjects with sustained viral suppression, dual therapy with NVP plus LPV/rtv at standard dosage was as potent and safe as standard-of-care HAART at 48 weeks of follow-up. This approach may reduce mitochondrial toxicity and improve LPV/rtv-associated lipid abnormalities. The results of this pilot study support the study of this approach in a larger, randomized trial.
Original languageEnglish
Pages (from-to)47-52
JournalJournal of Acquired Immune Deficiency Syndromes
Volume38
Issue number1
DOIs
Publication statusPublished - 1 Jan 2005

Keywords

  • Lipid profile
  • Lopinavir
  • Mitochondrial toxicity
  • Nevirapine
  • NRTI-sparing regimen
  • Pharmacokinetic study
  • Tolerability

Fingerprint Dive into the research topics of 'Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)'. Together they form a unique fingerprint.

  • Cite this

    Negredo, E., Moltó, J., Burger, D., Côté, H., Miró, O., Ribalta, J., Martínez, E., Puig, J., Ruiz, L., Salazar, J., López, S., Montaner, J., Rey-Joly, C., & Clotet, B. (2005). Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). Journal of Acquired Immune Deficiency Syndromes, 38(1), 47-52. https://doi.org/10.1097/00126334-200501010-00009